{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:54:37Z","timestamp":1780923277492,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10528-025-11094-3","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:38:41Z","timestamp":1745390321000},"page":"1786-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Downexpression of miR- 17 -\u20095p and miR- 125a- 5p is Potentially Associated with the Renal Impairment Through STAT- 3 and CD69 in Multiple Myeloma Adult Patients"],"prefix":"10.1007","volume":"64","author":[{"given":"Riham Abdel-Hamid","family":"Haroun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad M.","family":"Eweida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Samir","family":"Elsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Al-Dosoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer A.","family":"Elbedewy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab Alaa-Eldin","family":"Keshk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally M.","family":"Gamal-Eldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"10","key":"11094_CR1","doi-asserted-by":"publisher","first-page":"110473","DOI":"10.1016\/j.celrep.2022.110473","volume":"38","author":"AK Ajay","year":"2022","unstructured":"Ajay AK, Zhao L, Vig S, Fujiwara M, Thakurela S, Jadhav S, Cho A, Chiu IJ, Ding Y, Ramachandran K, Mithal A, Bhatt A, Chaluvadi P, Gupta MK, Shah SI, Sabbisetti VS, Waaga-Gasser AM, Frank DA, Murugaiyan G, Bonventre JV, Hsiao LL (2022) Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration. Cell Rep 38(10):110473. https:\/\/doi.org\/10.1016\/j.celrep.2022.110473","journal-title":"Cell Rep"},{"issue":"7","key":"11094_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/cells12071030","volume":"12","author":"SD Alipoor","year":"2023","unstructured":"Alipoor SD, Chang H (2023) Exosomal miRNAs in the tumor microenvironment of multiple myeloma. Cells 12(7):1030. https:\/\/doi.org\/10.3390\/cells12071030","journal-title":"Cells"},{"issue":"2","key":"11094_CR3","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.14800\/rd.1529","volume":"4","author":"M Alzrigat","year":"2017","unstructured":"Alzrigat M, Jernberg-Wiklund H (2017) The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis 4(2):e1529. https:\/\/doi.org\/10.14800\/rd.1529","journal-title":"RNA Dis"},{"issue":"10","key":"11094_CR4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","volume":"21","author":"BG Barwick","year":"2019","unstructured":"Barwick BG, Gupta VA, Vertino PM, Boise LH (2019) Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol 21(10):1121. https:\/\/doi.org\/10.3389\/fimmu.2019.01121","journal-title":"Front Immunol"},{"issue":"12","key":"11094_CR5","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1681\/ASN.2015091014","volume":"27","author":"F Bienaim\u00e9","year":"2016","unstructured":"Bienaim\u00e9 F, Muorah M, Yammine L, Burtin M, Nguyen C, Baron W, Garbay S, Viau A, Broueilh M, Blanc T, Peters D, Poli V, Anglicheau D, Friedlander G, Pontoglio M, Gallazzini M, Terzi F (2016) Stat3 controls tubulointerstitial communication during CKD. J Am Soc Nephrol 27(12):3690\u20133705. https:\/\/doi.org\/10.1681\/ASN.2015091014","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"11094_CR6","doi-asserted-by":"publisher","first-page":"e152418","DOI":"10.1172\/JCI152418","volume":"132","author":"R Blanco-Dom\u00ednguez","year":"2022","unstructured":"Blanco-Dom\u00ednguez R, de la Fuente H, Rodr\u00edguez C, Mart\u00edn-Aguado L, S\u00e1nchez-D\u00edaz R, Jim\u00e9nez-Alejandre R, Rodr\u00edguez-Arabaolaza I, Curtabbi A, Garc\u00eda-Guimaraes MM, Vera A, Rivero F, Cuesta J, Jim\u00e9nez-Borreguero LJ, Cecconi A, Duran-Cambra A, Taur\u00f3n M, Alonso J, Bueno H, Villalba-Orero M, Enr\u00edquez JA, Robson SC, Alfonso F, S\u00e1nchez-Madrid F, Mart\u00ednez-Gonz\u00e1lez J, Mart\u00edn P (2022) CD69 expression on regulatory T cells protects from immune damage after myocardial infarction. J Clin Invest 132(21):e152418. https:\/\/doi.org\/10.1172\/JCI152418","journal-title":"J Clin Invest"},{"issue":"3","key":"11094_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/biom14030360","volume":"14","author":"DV Bui","year":"2024","unstructured":"Bui DV, Nguyen LM, Kanda A, Chu HH, Le Thi NK, Yun Y, Kobayashi Y, Suzuki K, Mitani A, Shimamura A, Fukui K, Sawada S, Dombrowicz D, Iwai H (2024) CD69 signaling in eosinophils induces IL-10 production and apoptosis via the Erk1\/2 and JNK pathways, respectively. Biomolecules 14(3):360. https:\/\/doi.org\/10.3390\/biom14030360","journal-title":"Biomolecules"},{"issue":"6","key":"11094_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","volume":"107","author":"M Capra","year":"2022","unstructured":"Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse ML, Malinge L, Schwab S, Dimopoulos M (2022) Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica 107(6):1397\u20131409. https:\/\/doi.org\/10.3324\/haematol.2021.279229","journal-title":"Haematologica"},{"key":"11094_CR9","doi-asserted-by":"publisher","first-page":"153625","DOI":"10.1016\/j.prp.2021.153625","volume":"227","author":"X Chen","year":"2021","unstructured":"Chen X, Li R, Li X, Peng X, Zhang C, Liu K, Huang G, Lai Y (2021) Identification of a four-microRNA panel in serum for screening renal cell carcinoma. Pathol Res Pract 227:153625. https:\/\/doi.org\/10.1016\/j.prp.2021.153625","journal-title":"Pathol Res Pract"},{"issue":"2","key":"11094_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood-2018-06-860015","volume":"133","author":"M Dimopoulos","year":"2019","unstructured":"Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, Kimball AS, Mezzi K, Ludwig H, Niesvizky R (2019) Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood 133(2):147\u2013155. https:\/\/doi.org\/10.1182\/blood-2018-06-860015","journal-title":"Blood"},{"issue":"11","key":"11094_CR11","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/cancers14112585","volume":"14","author":"KY Du","year":"2022","unstructured":"Du KY, Qadir J, Yang BB, Yee AJ, Yang W (2022) Tracking miR-17-5p levels following expression of seven reported target mRNAs. Cancers (Basel) 14(11):2585. https:\/\/doi.org\/10.3390\/cancers14112585","journal-title":"Cancers (Basel)"},{"key":"11094_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2417085","author":"DS Elsaid","year":"2024","unstructured":"Elsaid DS, Elbedewy TAE, Hamza MA, Haroun RA (2024) The role of interleukin-20 and vascular endothelial growth factor-A biomarkers in the detection of renal impairment in patients with multiple myeloma. Expert Rev Hematol. https:\/\/doi.org\/10.1080\/17474086.2024.2417085","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"11094_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ncrna5020037","volume":"5","author":"C Federico","year":"2019","unstructured":"Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM (2019) Circulating microRNAs and their role in multiple myeloma. Noncoding RNA 5(2):37. https:\/\/doi.org\/10.3390\/ncrna5020037","journal-title":"Noncoding RNA"},{"issue":"10","key":"11094_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.molmed.2013.07.006","volume":"19","author":"R Gonz\u00e1lez-Amaro","year":"2013","unstructured":"Gonz\u00e1lez-Amaro R, Cort\u00e9s JR, S\u00e1nchez-Madrid F, Mart\u00edn P (2013) Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med 19(10):625\u2013632. https:\/\/doi.org\/10.1016\/j.molmed.2013.07.006","journal-title":"Trends Mol Med"},{"issue":"8","key":"11094_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00277-018-3316-7","volume":"97","author":"V Gonz\u00e1lez-Calle","year":"2018","unstructured":"Gonz\u00e1lez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP, Jain T, Chirackal S, Reeder C, Mikhael J, Noel P, Mayo A, Adams RH, Ahmann G, Braggio E, Stewart AK, Bergsagel PL, Van Wier SA, Fonseca R (2018) Evaluation of revised international staging system (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol 97(8):1453\u20131462. https:\/\/doi.org\/10.1007\/s00277-018-3316-7","journal-title":"Ann Hematol"},{"issue":"2","key":"11094_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3343\/alm.2024.0178","volume":"45","author":"Y Gu","year":"2025","unstructured":"Gu Y, Bi Y, Huang Z, Liao C, Li X, Hu H, Xie H, Huang Y (2025) CD69 expression is negatively associated with T-cell immunity and predicts antiviral therapy response in chronic hepatitis B. Ann Lab Med 45(2):185\u2013198. https:\/\/doi.org\/10.3343\/alm.2024.0178","journal-title":"Ann Lab Med"},{"issue":"17","key":"11094_CR17","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.3390\/cancers13174441","volume":"13","author":"T Harada","year":"2021","unstructured":"Harada T, Hiasa M, Teramachi J, Abe M (2021) Myeloma-bone interaction: a vicious cycle via TAK1-PIM2 signaling. Cancers (Basel) 13(17):4441. https:\/\/doi.org\/10.3390\/cancers13174441","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11094_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pathol.2021.09.006","volume":"54","author":"RA Haroun","year":"2022","unstructured":"Haroun RA, Osman WH, Amin RE, Hassan AK, Abo-Shanab WS, Eessa AM (2022) Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection. Pathology 54(1):104\u2013110. https:\/\/doi.org\/10.1016\/j.pathol.2021.09.006","journal-title":"Pathology"},{"issue":"1","key":"11094_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s43141-023-00565-y","volume":"21","author":"RA Haroun","year":"2023","unstructured":"Haroun RA, Osman WH, Eessa AM (2023) Prognostic significance of serum miR-18a-5p in severe COVID-19 Egyptian patients. J Genet Eng Biotechnol 21(1):114. https:\/\/doi.org\/10.1186\/s43141-023-00565-y","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"11094_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K (2024) Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res 43(1):23. https:\/\/doi.org\/10.1186\/s13046-024-02949-5","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"11094_CR22","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.3390\/cancers15235585","volume":"15","author":"M Johansen","year":"2023","unstructured":"Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen M\u00d8, Andersen TL, Abildgaard N, Lund T (2023) Novel developments in the treatment of multiple myeloma-associated bone disease. Cancers (Basel) 15(23):5585. https:\/\/doi.org\/10.3390\/cancers15235585","journal-title":"Cancers (Basel)"},{"issue":"12","key":"11094_CR23","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1002\/cam4.3050","volume":"9","author":"H Kobayashi","year":"2020","unstructured":"Kobayashi H, Terao T, Tsushima T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K (2020) Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma. Cancer Med 9(12):4460\u20134466. https:\/\/doi.org\/10.1002\/cam4.3050","journal-title":"Cancer Med"},{"issue":"9","key":"11094_CR24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-019-1854-0","volume":"10","author":"Y Kong","year":"2019","unstructured":"Kong Y, Hu L, Lu K, Wang Y, Xie Y, Gao L, Yang G, Xie B, He W, Chen G, Wu H, Wu X, Zhan F, Shi J (2019) Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma. Cell Death Dis 10(9):624. https:\/\/doi.org\/10.1038\/s41419-019-1854-0","journal-title":"Cell Death Dis"},{"issue":"41","key":"11094_CR25","doi-asserted-by":"publisher","first-page":"12812","DOI":"10.1073\/pnas.1507094112","volume":"112","author":"S Landskroner-Eiger","year":"2015","unstructured":"Landskroner-Eiger S, Qiu C, Perrotta P, Siragusa M, Lee MY, Ulrich V, Luciano AK, Zhuang ZW, Corti F, Simons M, Montgomery RL, Wu D, Yu J, Sessa WC (2015) Endothelial miR-17\u223c92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Proc Natl Acad Sci U S A 112(41):12812\u201312817. https:\/\/doi.org\/10.1073\/pnas.1507094112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"11094_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S439969","volume":"9","author":"Y Li","year":"2024","unstructured":"Li Y, Gu Y, Yang P, Wang Y, Yu X, Li Y, Jin Z, Xu L (2024) CD69 is a promising immunotherapy and prognosis prediction target in cancer. Immunotargets Ther 9(13):1\u201314. https:\/\/doi.org\/10.2147\/ITT.S439969","journal-title":"Immunotargets Ther"},{"issue":"9","key":"11094_CR27","doi-asserted-by":"publisher","first-page":"15763","DOI":"10.18632\/oncotarget.15000","volume":"8","author":"XH Liao","year":"2017","unstructured":"Liao XH, Xiang Y, Yu CX, Li JP, Li H, Nie Q, Hu P, Zhou J, Zhang TC (2017) STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget 8(9):15763\u201315774. https:\/\/doi.org\/10.18632\/oncotarget.15000","journal-title":"Oncotarget"},{"issue":"18","key":"11094_CR28","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.7150\/thno.76852","volume":"12","author":"R Liu","year":"2022","unstructured":"Liu R, Zhong Y, Chen R, Chu C, Liu G, Zhou Y, Huang Y, Fang Z, Liu H (2022) m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics 12(18):7760\u20137774. https:\/\/doi.org\/10.7150\/thno.76852","journal-title":"Theranostics"},{"issue":"20","key":"11094_CR29","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.21037\/atm-21-4678","volume":"9","author":"M Ma","year":"2021","unstructured":"Ma M, Fu L, Jia Z, Zhong Q, Huang Z, Wang X, Fan Y, Lin T, Song T (2021) miR-17-5p attenuates kidney ischemia-reperfusion injury by inhibiting the PTEN and BIM pathways. Ann Transl Med 9(20):1545. https:\/\/doi.org\/10.21037\/atm-21-4678","journal-title":"Ann Transl Med"},{"issue":"10","key":"11094_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","volume":"132","author":"E Morelli","year":"2018","unstructured":"Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gull\u00e0 A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P (2018) Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood 132(10):1050\u20131063. https:\/\/doi.org\/10.1182\/blood-2018-03-836601","journal-title":"Blood"},{"issue":"6","key":"11094_CR31","doi-asserted-by":"publisher","first-page":"101074","DOI":"10.1016\/j.jhepr.2024.101074","volume":"6","author":"C Niehaus","year":"2024","unstructured":"Niehaus C, Klein S, Strunz B, Freyer E, Maasoumy B, Wedemeyer H, Bj\u00f6rkstr\u00f6m NK, Kraft ARM, Cornberg M (2024) CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis. JHEP Rep 6(6):101074. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101074","journal-title":"JHEP Rep"},{"issue":"6","key":"11094_CR32","doi-asserted-by":"publisher","first-page":"F1151","DOI":"10.1152\/ajprenal.00034.2019","volume":"316","author":"J Pace","year":"2019","unstructured":"Pace J, Paladugu P, Das B, He JC, Mallipattu SK (2019) Targeting STAT3 signaling in kidney disease. Am J Physiol Renal Physiol 316(6):F1151\u2013F1161. https:\/\/doi.org\/10.1152\/ajprenal.00034.2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"15","key":"11094_CR33","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.7150\/jca.97102","volume":"15","author":"L Pan","year":"2024","unstructured":"Pan L, Qin Z, Zhou Q, Zheng P, Li H, Zhou X, Qin Y (2024) Unlocking the therapeutic potential: harnessing miR-125a-5p to enhance autophagy and apoptosis in pancreatic cancer through targeting STAT3. J Cancer 15(15):4955\u20134968. https:\/\/doi.org\/10.7150\/jca.97102","journal-title":"J Cancer"},{"issue":"3","key":"11094_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ki.2010.154","volume":"78","author":"M Pang","year":"2010","unstructured":"Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD, Zhuang S (2010) A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78(3):257\u2013268. https:\/\/doi.org\/10.1038\/ki.2010.154","journal-title":"Kidney Int"},{"issue":"12","key":"11094_CR35","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"11094_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/mmr.2024.13263","volume":"30","author":"J Sun","year":"2024","unstructured":"Sun J, Niu L, Wang Y, Zhao G, Tang L, Jiang J, Pan S, Ge X (2024) MicroRNA 17 5p alleviates sepsis related acute kidney injury in mice by modulating inflammation and apoptosis. Mol Med Rep 30(2):139. https:\/\/doi.org\/10.3892\/mmr.2024.13263","journal-title":"Mol Med Rep"},{"issue":"5","key":"11094_CR37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","volume":"105","author":"PJ Teoh","year":"2020","unstructured":"Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ (2020) IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica 105(5):1391\u20131404. https:\/\/doi.org\/10.3324\/haematol.2019.221176","journal-title":"Haematologica"},{"issue":"3","key":"11094_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.leukres.2012.11.011","volume":"37","author":"D Vasilatou","year":"2013","unstructured":"Vasilatou D, Papageorgiou SG, Kontsioti F, Kontos CK, Tsiotra P, Mpakou V, Pavlou MA, Economopoulou C, Dimitriadis G, Dervenoulas J, Pappa V (2013) Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes. Leuk Res 37(3):251\u2013258. https:\/\/doi.org\/10.1016\/j.leukres.2012.11.011","journal-title":"Leuk Res"},{"issue":"9","key":"11094_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.neo.2019.06.004","volume":"21","author":"DT Vo","year":"2019","unstructured":"Vo DT, Karanam NK, Ding L, Saha D, Yordy JS, Giri U, Heymach JV, Story MD (2019) miR-125a-5p functions as tumor suppressor microRNA and is a marker of locoregional recurrence and poor prognosis in head and neck cancer. Neoplasia 21(9):849\u2013862. https:\/\/doi.org\/10.1016\/j.neo.2019.06.004","journal-title":"Neoplasia"},{"issue":"20","key":"11094_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12935-020-1096-3","volume":"10","author":"JX Wang","year":"2020","unstructured":"Wang JX, Jia XJ, Liu Y, Dong JH, Ren XM, Xu O, Liu SH, Shan CG (2020) Silencing of miR-17-5p suppresses cell proliferation and promotes cell apoptosis by directly targeting PIK3R1 in laryngeal squamous cell carcinoma. Cancer Cell Int 10(20):14. https:\/\/doi.org\/10.1186\/s12935-020-1096-3","journal-title":"Cancer Cell Int"},{"issue":"12","key":"11094_CR41","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1002\/ijc.33528","volume":"148","author":"P Xiang","year":"2021","unstructured":"Xiang P, Yeung YT, Wang J, Wu Q, Du R, Huang C, Jia X, Gao Y, Zhi Y, Guo F, Wei H, Zhang D, Liu Y, Liu L, Liang L, Wang J, Song Y, Liu K, Fang B (2021) miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. Int J Cancer 148(12):3071\u20133085. https:\/\/doi.org\/10.1002\/ijc.33528","journal-title":"Int J Cancer"},{"key":"11094_CR42","doi-asserted-by":"publisher","first-page":"119657","DOI":"10.1016\/j.lfs.2021.119657","volume":"288","author":"C Yang","year":"2022","unstructured":"Yang C, Yang C, Huang Z, Zhang J, Chen N, Guo Y, Zahoor A, Deng G (2022) Reduced expression of MiR-125a-5p aggravates LPS-induced experimental acute kidney injury pathology by targeting TRAF6. Life Sci 288:119657. https:\/\/doi.org\/10.1016\/j.lfs.2021.119657","journal-title":"Life Sci"},{"issue":"9","key":"11094_CR43","doi-asserted-by":"publisher","first-page":"e23399","DOI":"10.1002\/jcla.23399","volume":"34","author":"H Yu","year":"2020","unstructured":"Yu H, Peng S, Chen X, Han S, Luo J (2020) Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. J Clin Lab Anal 34(9):e23399. https:\/\/doi.org\/10.1002\/jcla.23399","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"11094_CR44","doi-asserted-by":"publisher","first-page":"918","DOI":"10.7150\/jca.65614","volume":"13","author":"W Yu","year":"2022","unstructured":"Yu W, Wang J, Li C, Xuan M, Han S, Zhang Y, Liu P, Zhao Z (2022) miR-17-5p promotes the invasion and migration of colorectal cancer by regulating HSPB2. J Cancer 13(3):918\u2013931. https:\/\/doi.org\/10.7150\/jca.65614","journal-title":"J Cancer"},{"issue":"4","key":"11094_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7150\/jca.33696","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wan X, Tang S, Li K, Wang Y, Liu Y, Sha Q, Zha X, Liu Y (2020) miR-125b-5p\/STAT3 pathway regulated by mTORC1 plays a critical role in promoting cell proliferation and tumor growth. J Cancer 11(4):919\u2013931. https:\/\/doi.org\/10.7150\/jca.33696","journal-title":"J Cancer"},{"issue":"9","key":"11094_CR46","doi-asserted-by":"publisher","first-page":"958","DOI":"10.7499\/j.issn.1008-8830.2003329","volume":"22","author":"YR Zhang","year":"2020","unstructured":"Zhang YR, Wu YF, Wang H, Lin XM, Zhang XM (2020) Role of microRNA-17-5p in the pathogenesis of pediatric nephrotic syndrome and related mechanisms. Zhongguo Dang Dai Er Ke Za Zhi 22(9):958\u2013963. https:\/\/doi.org\/10.7499\/j.issn.1008-8830.2003329. (Chinese)","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"1","key":"11094_CR47","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, Hu Y, Huang H (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606. https:\/\/doi.org\/10.1186\/s12885-021-08280-y","journal-title":"BMC Cancer"},{"issue":"46","key":"11094_CR48","doi-asserted-by":"publisher","first-page":"e5202","DOI":"10.1097\/MD.0000000000005202","volume":"95","author":"W Zhu","year":"2016","unstructured":"Zhu W, Chen W (2016) Bortezomib-based treatment for multiple myeloma patients with renal impairment: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 95(46):e5202. https:\/\/doi.org\/10.1097\/MD.0000000000005202","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"11094_CR49","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.3892\/ol.2018.8157","volume":"15","author":"B Zhu","year":"2018","unstructured":"Zhu B, Ju S, Chu H, Shen X, Zhang Y, Luo X, Cong H (2018) The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol Lett 15(5):6094\u20136106. https:\/\/doi.org\/10.3892\/ol.2018.8157","journal-title":"Oncol Lett"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-025-11094-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-025-11094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:40:50Z","timestamp":1776393650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-025-11094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["11094"],"URL":"https:\/\/doi.org\/10.1007\/s10528-025-11094-3","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of Tanta University\u2019s medical faculty in Tanta, Egypt, and the Declaration of Helsinki\u2019s ethical guidelines are both followed in this study (3626PR814\/8\/24).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"In accordance with the local ethical commission\u2019s instructions, informed consent was given by each patient. Every patient file, including all investigations, had a code number, which guaranteed the confidentiality of all patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}